Deitiforine, an antiinfluenza chemotherapeutic

Antibiotiki i Khimioterapiya

Volumn 58, Issue 1-2, 2013, Pages 36-48

  Dura, S N Tan ^a   Zarubaev, V V ^b   Anfimov, P M ^b   Kiselev, O I ^b  

^a N D ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

^b Influenza Research Institute   (Russian Federation)

Author keywords

Antiinfluenza activity; Deitiforine; Influenza; Prophylaxis; Therapy

Indexed keywords

ANTIVIRUS AGENT; DEITIPHORIN; ORGANIC COMPOUND;

ANIMAL; ANTIVIRAL RESISTANCE; CHICK EMBRYO; CULTURE TECHNIQUE; DRUG EFFECT; HUMAN; INFLUENZA; INFLUENZA VIRUS A; REVIEW;

ANIMALS; ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; CHICK EMBRYO; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; ORGANIC CHEMICALS;

EID: 84889603310     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Rivera S. J. Avian influenza (H5N1) - The next pandemic? In print 2006; 53:3:56, 58, 62.
2. Enserink M. Avian influenza - H5N1 moves into Africa, European Union, deepening global crisis. Science 2006; 311: 5763: 932.
3. Peiris J. S. M., de Jong M. D., Guart Y. Avian influenza virus (H5N1): A threat to human health. Clin Microbiol Rev 2007; 20:2: 243-267.
4. Wolinsky S. M. The monster at our door - The global threat of avian flu. Science 2006; 311:5762:780-781.
5. Flahault A. Global monitoring of influenza: potential contribution of national networks from a French perspective. Expert Rev Antiinfect Ther 2006; 4: 3: 387-393.
6. Enserink M. Avian influenza. Pushed by an outsider, scientists call for global plan to share flu data. Science 2006; 313:5790:1026.
7. Colizza V., Barrat A., Barthelemy U., Vespignani A. The role of the airline transportation network in the prediction and predictability of global epidemics. Proc Nat Acad Scien USA 2006; 103:7: 2015-2020.
8. Ferguson N. M., Cummings D. A., Eraser C., Cajka J. C., Cooley P. C., Burke D. S. Strategies for mitigating an influenza pandemic. Nature 2006; 442:7101:448-452.
9. Sugrue R. J., Tan B.-H., Yeo D. S., Sutejo R. Antiviral drugs for the control of pandemic influenza virus. Ann Acad Med. Singapore 2008; 37:6: 518-524.
10. Narain J. P., Kumar R., Bhatia R. Pandemic (H IN 1)2009: epidemiological, clinical and prevention aspects. Nat Med J India. 2009; 22: 5: e1-e6.
11. Meanwell N. A., Belema M., Carini D. J., D'Andrea, S. V., Kadow J. F., Krystal M., Naidu B. N., Regueiro-Ren A., Scola P. M., Sit S. Y., Walker M. A., Wang T., and Yeung K. S. Developments in antiviral drug design, discovery and development in 2004. [Review], CurrDrugTarg- Infect Dis 2005; 5:4: 307-400.
12. McCullersJ. A. The clinical need for new antiviral drugs directed against influenza virus. J Infect Dis 2006; 193: 6: 751-753.
13. Islam T., von Itzstein M. Anti-influenza drug discovery: Are we ready for the next pandemic? Advan Caibohyd Chem Biochem 2008; 61:293-352.
14. Lipsitch M., Cohen T., Murray M., Levin B. R. Antiviral resistance and the control of pandemic influenza. PLoS Medicine 2007; 4: 1:111-121.
15. Handel A., Regoes R. R., Anlia R. The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol 2006; 2: 10: 1262-1270.
16. Moghadas S. M., Bowman C. S., Rosl G, Wu J. Population-wide emergence of antiviral resistance during pandemic influenza. PLoS One 2008; 3:3:1-8.
17. Alexander M. E., Bowman C. S., FengZ., Gardam M., Moghadas S. M., Rost G., Wu J., Yan P. Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proc Royal Soc London B. 2007; 274:1619:1675-1684.
18. Geldenhuys W. J., Malan S.F., BloomquistJ. R., MarchandA. P., van der Schy C. J. Pharmacology and structure-activity relationships ofbioac- Tive polycyclic cage compounds: A focus on pentacycloundecane derivatives. Med Res Rev 2005; 25: 1: 21-48.
19. Zoidis G., Fylas C., Papanastasiou L., Foscolos G. B., Fytas G., Padalko E., de ClercqE., HaesensL., NeytsJ., KolocourisN. Heterocyclic rimantadine analogues with antiviral activity. Biooig Medic Chem 2006; 14: 10: 3341-3348.
20. Antiviral drug therapy. Amer Fam Phys 1991; 43:1:197-204.
21. Prober C. G. Antiviral therapy for influenza virus infections. Semin Pediatr Infect Dis 2002; 13:1:31-39.
22. Townsend K. A., Eiland L. S. Combating influenza with antiviral therapy in the pediatric population. Pharmacotherapy 2006; 26: 1: 95-103.
23. Clercq E. Influenza virus inhibitors available for the chemotherapy and/or chemoprophylaxis of influenza virus infections. Verh K Acad Geneeskd Belg 2006; 68:2:121-137.
24. Kotlerova E., Betakova T. Influenza viruses and their ion channels (Review). Acta Virologica 2006; 50:1: 7-16.
25. Pinto L. H. and Lamb R. A. The M2 proton channels of influenza A and B viruses. J Biol Chem 2006; 281:14:8997-9000.
26. Bensky D., Gamble A. Chinese Herbal Medicine: Materia Medica. 1993.
27. Huang Bingshan, Wang Yuxia. Thousand formulas and thousand herbs of traditional Chinese medicine. Heilongjiang Education Press. Haibin. 1993.
28. Vbtiakov V. I., Erokhlna I. R., Amvms'eva N. V., Ruslaev V. A. Pathology of the reproductive apparatus of cells under the action of remantadine and deitiforin. Biull Eksp Biol Med 1989; 108:9:356-358.
29. Deyde V. U., Sheu T. G., TrujilloA.A, Okomo-Adhiambo M., Garten R., KlimovA. I., Gubareva L. V. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 2010; 54:3:1102-1110.
30. Vmycianu N., Zhtrebtsova E., Grygoreva T. Therapeutical effect of modified adamantane copolymer compounds: study of molecular mechanisms. Acta Biochimica Polonica 2001; 48: 1: 241-249.
31. Hay A. J. The action of adamantanines against influenza A viruses inhibition of the M2 ion channel protein. Sem Virol 1992; 3:21-30.
32. Kiselev O. I. Influenza Antiviral Drug Discovery. In: Strengthening Influenza Pandemic Preparedness Through Civil-Military Cooperation*. Eds. James Neville. Oleg I. Kiselev. NATO Public Diplomacy Division. NATO Science Series. 2003; 360:47-56.
33. Rosenberg M. H, Casarotto M. G. Coexistence of two adamantane binding sites in the influenza A M2 ion channel. Proc Natl Acad Sci USA 2010; 107:31:13866-13871.
34. Pielak R. M., Schnell J. R., Chou J. J. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci USA 2009; 106: 18:7379-7384.
35. Du Q.-S., Wang S.-Q., Huang R.-B., Chou K.-C. Computational 3D structures of drug-targeting proteins in the 2009-H1N1 influenza A virus. Chem Phys Lett 2010; 485:191-195.
36. YiM., Cross T. A., Zhou H.-X. Conformational heterogeneity of the M2 proton channel and a structural model for channel activation. Proc Natl Acad Sci USA 2009; 106:32:13311-13316.
37. Cheng P. K. C., Leung T. W. C., Ho E C. M., Leung P. C. K., NgA. Y. Y., Lai M. Y. Y. and Lim W. W. L. Oseltamivir- And amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 2009; 15:6:966-968.
38. Bright R. A., Shay D. K., Shu B, Cox N. J., Klimov A. I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295: 8:891-894.
39. Deyde V. M., Xu X., Bright R. A., Shaw M., Smith C. B., Zhang Y., Shu Y., Gubareva L. V., Cox N./., KlimovA. I. Surveillance of resistance to adamantanes among influenza A(H3N2 and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196: 2: 249-257.
40. Wang J.-F, Wei D.-Q., Chou K.-C. Insights from investigating the interactions of adamantane-based drugs with the M2 proton channel from the H1N1 swine virus. Biochem Biophys Res Commun 2009; 388: 2:413-417.
41. Moghadas S. M., Bowman C. S., Rost G., Wu J. Population-wide emergence of antiviral resistance during pandemic influenza. PLoS One 2008; 3:3:1-8.
42. Nguyen J. T., HoopesJ. D., Le M. II, SmeeD. F., PatickA. K., FaixD. J., Blair P. J., de Jong M. D., Prichard M. N., Went G. T. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 5:2: e9332.
43. Wu J. T., Leung G. M., Lipsilch M., Cooper B. S., Riley S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 2009; 6: 5: el000085.
44. Regoes R. R., Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006; 31.
45. Brockmann S. O., Schwehm M., Duerr H. P., Witschi M., Koch D., Vidondo B., Eichner M. Modeling the effects of drug resistant influenza virus in a pandemic. Vir J 2008; 5: 133-138.